Associate Professor St. John's University Jamaica, New York
In last 5 years, there has been a huge surge in the research and FDA approvals of bRo5 drug molecules which includes nucleic acid-based agents (siRNA, gene and mRNA), PROteolysis Targeting Chimera (PROTACs), novel class of protein and peptide etc. Undoubtedly, these next generation therapeutics are significantly more effective than small molecules inhibitors. However, their size, solubility, permeability, and stability are not favorable for extravascular absorption. Reaching to target site in therapeutically effective concentration is paramount for clinical success irrespective of the potency in vitro assays. It is imperative to use advanced formulation technologies for the proficient delivery of next generation molecules. Lipid nanoparticles with novel class of ionizable lipids, diseased tissue specific delivery, hydrophobic ion-pairing agents and long acting injectable depot formulation are some the successful approaches to tackle the delivery challenges of such molecules. In this session, we can cover the physicochemical characteristics of bRo5 molecules, challenges in delivery and clinically viable formulation strategies.
Learning Objectives:
Describe challanges of bRo5 molecules
Translation formulation technologies and high functionality excipients for encapsulating next generation bRo5 molecules
Oral and patenteral delivery systems for bRo5 molecules, peptides and nucleic acid based therapeutics